Vertex Pharmaceuticals, a biotech firm specializing in treatments for cystic fibrosis (CF), has developed several therapies for CF patients with specific gene mutations. The company offers TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for individuals with CF and at least one F508del mutation aged six and above. For homozygous F508del patients aged two and above, Vertex offers ORKAMBI, while KALYDECO treats individuals with CF aged four months and above with a mutation that responds to ivacaftor, R117H mutation, or certain gating mutations. The company's pipeline includes the CF mRNA therapeutic VX-522, currently undergoing Phase 1 clinical trials, as well as VX-548, a non-opioid pain medication in Phase 3 clinical trials. In addition, Vertex is working on Exa-cel to treat sickle cell disease and transfusion-dependent beta thalassemia, and VX-864 for AAT deficiency, both of which are in Phase 2 clinical trials. The company is also involved in developing VX-147 to treat APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension, in a single Phase 2/3 clinical trial. Vertex distributes its products to specialty pharmacies and distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. It has also partnered with CRISPR Therapeutics AG., Moderna, Inc., Entrada Therapeutics, Inc., and other firms to develop new treatments. Based in Boston, Massachusetts, Vertex Pharmaceuticals was founded in 1989.
Vertex Pharmaceuticals's ticker is VRTX
The company's shares trade on the NASDAQ stock exchange
They are based in Boston, Massachusetts
There are 1001-5000 employees working at Vertex Pharmaceuticals
It is vrtx.com
Vertex Pharmaceuticals is in the Healthcare sector
Vertex Pharmaceuticals is in the Biotechnology industry
The following five companies are Vertex Pharmaceuticals's industry peers: